LTRN
Lantern Pharma Inc.
Key Financials
Operating Income
$-17978494
↑ 19.1%
EPS (Diluted)
$-1.57
↑ 18.7%
Total Liabilities
$4.5M
↑ 2.7%
Net Income
$-17119438
↑ 17.6%
Total Assets
$11.0M
↓ 56.8%
Shareholders' Equity
$6.5M
↓ 69.2%
Cash & Equivalents
$4.4M
↓ 41.1%
Operating Cash Flow
$-15676980.00
↑ 12.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13D/A | 4/16/2026 | View on SEC |
| 8-K | 4/10/2026 | View on SEC |
| SCHEDULE 13G | 4/3/2026 | View on SEC |
| 424B5 | 3/30/2026 | View on SEC |
| 10-K | 3/30/2026 | View on SEC |
| 8-K | 3/30/2026 | View on SEC |
| SCHEDULE 13D/A | 2/23/2026 | View on SEC |
| 8-K | 1/23/2026 | View on SEC |
| 4 | 1/13/2026 | View on SEC |
| 4 | 1/13/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | LTRN |
| Company Name | Lantern Pharma Inc. |
| CIK | 1763950 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | TX |
| Phone | 972-277-1136 |